Reports Q3 revenue $1.08M, consensus $1.64M. “With the completion of the transformative sale of our FibroGen (FGEN) China operations, we have significantly simplified our capital structure and extended our cash runway into 2028. Notably, we initiated the Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis anticipated in the second half of 2026,” said Thane Wettig, Chief Executive Officer, FibroGen. “We remain on track to submit the Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025 and continue to assess its development options. We are excited to continue building on the strong momentum we have gained throughout this year.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FGEN Upcoming Earnings Report: What to Expect?
- FibroGen Receives $6.4 Million Payment from AstraZeneca
- Hold Rating on FibroGen’s FG-3246 Amid Competitive Prostate Cancer Treatment Landscape and Upcoming Trial Data
- FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat
- FibroGen initiates Phase 2 trial of FG-3246